key: cord-0015263-23x04vnq
authors: KHAMMESRI, Siripat; MATHURA, Yaoprapa; BOONPRASERT, Khajohnpat; AMPASAVATE, Chadarat; HONGWISET, Darunee; BROWN, Janine L; THITARAM, Chatchote
title: Successful treatment of elephant endotheliotropic herpesvirus infection in an Asian elephant (Elephas maximus) calf by oral acyclovir medication: Case report
date: 2020-11-25
journal: J Vet Med Sci
DOI: 10.1292/jvms.20-0375
sha: d7f886889ce42685730503706a366d36aa7ce475
doc_id: 15263
cord_uid: 23x04vnq

Elephant endotheliotropic herpesvirus (EEHV) is a major cause of death in Asian elephant (Elephas maximus) calves. A 2-year, 11-month-old female, captive Asian elephant presented with facial edema and a mild fever. Blood samples were collected and showed EEHV1A positivity with a high viral load by real time PCR. Heterophil toxicity also was reported for the first time in this case. The calf was treated orally with acyclovir, 45 mg/kg tid for 28 days, which reduced the EEHV1A viral load to undetectable levels within 9 days and the calf survived. A successful outcome with oral acyclovir administration provides another and affordable option to treat EEHV hemorrhagic disease in Asian elephants, and one that is easier to administer in untrained calves.

The calf, 2 years and 11 months old and weaned, was housed in a tourist camp in northern Thailand and exhibited slight facial edema and mild fever (37.5°C; normal range 36-37°C), but no other clinical signs. Blood was collected from an ear vein in ethylenediaminetetraacetic acid-coated tubes and submitted to the diagnostic laboratory at the Faculty of Veterinary Medicine, Chiang Mai University to confirm EEHV by real-time polymerase chain reaction (qPCR) analysis [18] . The day of the first positive qPCR test to EEHV1A was designated as Day 0 [29, 31] . Acyclovir 800 mg tablets (HERPENON 800; Polipharm, Samut Prakan, Thailand) were then administered in a banana starting 24 hr later (Day 1, or 3 days after clinical signs), and continued daily for 28 days. Due to the poor bioavailability observed in horse acyclovir pharmacokinetic studies (10-20 mg/kg oral acyclovir had only 1.5-2.8% bioavailability [1, 8] ), a dose of 45 mg/kg, tid PO, was calculated taking into consideration the digestive system of the elephant (hindgut fermentation) with interspecies allometric scaling as described by Hunter [13] . Flunixin meglumine (50 mg/ml, 2 mg/kg i.m.) (NIGLUMINE; Calier, Barcelona, Spain) was administered when the calf's temperature exceeded 37°C ( Days 4, 9, 12) to reduce fever. Vitamin C 500 mg tablets (ZEE-500; Patar Lab, Pathum Thani, Thailand; 5,000 mg/day) had been given orally to the calf for 2 years prior to EEHV diagnosis and was continued throughout the study. Manual complete blood counts, blood chemistry tests using an Auto Hematology Analyzer (Mindray BC5300; Mindray Medical, Shenzhen, China) and Biochemical Analyzer (Vitalab Flexor XL; Vital Scientific NV., Dieren, The Netherlands), and qPCR assays were conducted every 1-2 days during treatment. On the final day of treatment (Day 28), when plasma acyclovir concentration was assumed to reach steady-state, blood was collected and the acyclovir concentration determined by high-pressure liquid chromatography, mass spectrometry (LC-MS/MS) (API 3200 AB, Sciex, Framingham, MA, USA) at the Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University as described for horses [1, 8, 32] . Pharmacokinetic data to base the dose and frequency of administration are lacking for antiviral drugs in elephants. Thus, the decision to stop treatment on Day 28 was based on the viral load having been low or undetectable for 7 consecutive days and over concern about possible adverse side effects, like kidney damage, of longer-term administration [12] .

The initial EEHV1A load was 2.96 × 10 4 viral genome copies (vgc)/ml, with a 22.21 cycle threshold (CT), which increased through Day 7 to a peak of 1.15 × 10 6 vgc/ml and 14.74 CT ( Fig. 1) , although day-to-day variability was high with no apparent explanation. The viral load was then undetectable on Day 8 and remained at a low level (<1,000 vgc/ml with CT value >30) throughout the remainder of the treatment period. The plasma acyclovir concentration on Day 28 was 3.56 µg/ml, which was assumed to represent a pharmacokinetic steady state based on data in humans. For example, acyclovir concentrations reached a steady state at 4-5 times after repeating doses [10] , and exceeded the 50% maximal inhibitory concentration (IC 50 ) during treatment of herpes simplex virus (HSV) HSV-1 (0.02-0.9 µg/ml) and HSV-2 (0.03-2.2 µg/ml) in human in vitro studies [24] .

Nephrotoxicity, which is a major side effect of acyclovir treatment in humans [16, 23, 25] , was not observed in this calf based on blood chemistry analyzes. No discernable changes in blood urea nitrogen (mg/dl) or creatinine (mg/dl) were observed over the 28day treatment period in our study. All of these parameters were within the normal range [14] . Moreover, long-term use of acyclovir in humans prevented the recurrent of HSV-1 and HSV-2, with no adverse clinical drug reactions noted [9, 21] . Packed cell volume and platelet counts monitored to assess disease progression also fell within normal ranges throughout the evaluation period (Fig.  1) . Heterophil left-shifting and toxicity were observed on the day of clinical sign onset and when the viral load was high (Day 0) ( Table 1) . Heterophils were scored as moderate based on Stacy et al. [28] , showed a lack of nuclear constrictions and smooth parallel nuclear walls, with a single clear vacuole and presence of moderate cytoplasmic basophilia (Fig. 2) . Toxic neutrophils and band cells also have been reported in association with systemic inflammatory responses in horses [17] . Thus, scoring of heterophil toxicity was useful for evaluating the progression of EEHV and treatment efficacy in this calf.

Administration of 5,000 mg Vitamin C both prior to and during treatment may have increased the calf's immune response. Vitamin C has been used as an immunomodulatory agent [22] in treatment of a number of viruses, including poliovirus, Venezuelan equine encephalitis, human lymphotropic virus type 1, human immunodeficiency virus, parvovirus and rabies due to positive effects on leucocytes, lymphocytes, and macrophages. Vitamin C also increases neutrophil phagocytic capacity and oxidative killing, and supports lymphocyte proliferation and function by improving chemotaxis [5] . The fact that this calf had been treated prophylactically with Vitamin C for nearly 2 years prior may have improved its outcome. This is the first report to confirm oral acyclovir treatment reduced a high EEHV1A viral load to concentrations below the cut-off level by Day 5, although it increased again on Day 7, which may have been related to detection of dead viruses or viral gene fragments [15] , and so should be investigated more in the future. The viral load pattern in our study was similar to that of Stanton [30] , where clinical signs were in accordance with the pattern reflecting a true infection. In a previous case [27] , successful treatment of EEHV1A was achieved using oral acyclovir (24 mg/kg) for 2 days and then intravenous acyclovir (12 mg/kg) twice a day, with supportive antibiotics (penicillin G), vitamin C, and fluid therapy. In that study, the viral load was decreased after 2 weeks of treatment and reached undetectable levels within 1 month. In another report [26] , loading doses of oral famciclovir were given to two EEHV positive calves in the first few days of infection, which were then reduced during subsequent days and resulted in recovery 3-4 weeks following. Thus, loading dose regimens for oral acyclovir may be more therapeutic by reaching high circulating drug concentrations more quickly. In cases of well-trained calves, an intravenous route should be considered to reach rapid therapeutic blood concentrations, whereas an oral route may be more appropriate for wild or untrained elephants. However, plasma acyclovir concentrations, an important parameter for determining appropriate dose regimens, were not determined in either of those studies. And although not noted in this study, side effects and toxicity can occur during and after antiviral treatment and should be carefully monitored. The successful outcome in this case undoubtedly was due to early diagnosis and treatment, as that is known to be key to survival in EEHV-HD cases [2, 12, 20, 27] , while unsuccessful cases often are related to late diagnosis and treatment even when antiviral drugs are administered.

Finally, this was the first report of heterophil toxicity associated with EEHV in Asian elephants, which provided additional data on the health status of this calf. More work is needed to fully characterize the pharmacokinetics of oral acyclovir treatment using frequent blood samples over time, and different treatment dose and frequency regimens to establish effective protocols. Overall results suggest an oral form of acyclovir may be an effective treatment for EEHV, and an alternative to injectable forms to improve calf compliance. Fig. 2 . Heterophil left-shifting and toxicity with a monocyte and lymphocyte in a blood smear collected, ×40 objective (a, b). A band heterophil that lacked nuclear constrictions and smooth parallel nuclear walls (c, d, e) and a heterophil with moderate cytoplasmic basophilia, ×100 objective (f, g, h). Wright Giemsa stain.

Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses

Endotheliotropic herpesvirus treatments in a wild orphan baby Asian elephant (Elephas maximus)

Survival analysis of confirmed elephant endotheliotropic herpes virus cases in Thailand from

Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus)

The antiviral properties of vitamin C

Elephant endotheliotrophic herpes virus (EEHV) protocol. United Kingdom Elephant Health Programme

Surviving and fatal Elephant Endotheliotropic Herpesvirus-1A infections in juvenile Asian elephants -lessons learned and recommendations on anti-herpesviral therapy

Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses

Acyclovir Study Group 1993. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark

Principles and basic concepts of toxicokinetics

Houston Zoo Asian Elephant EEHV Protocol

In: Fowler's Zoo and Wild Animal Medicine Current Therapy

Concepts and issues with interspecies scaling in zoological pharmacology

Hematologic and biochemical reference intervals for captive Asian elephants (Elephas maximus) in Thailand

Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection?

Risk of acute kidney injury from oral acyclovir: a population-based study

Association of presence of band cells and toxic neutrophils with systemic inflammatory response syndrome and outcome in horses with acute disease

Detection and evaluation of novel herpesviruses in routine and pathological samples from Asian and African elephants: identification of two new probosciviruses (EEHV5 and EEHV6) and two new gammaherpesviruses (EGHV3B and EGHV5)

Review of elephant endotheliotropic herpesviruses and acute hemorrhagic disease

Guidelines for Management Elephant Endotheliotropic Herpesvirus (EEHV) in Asia Recommendations from the 1st Asian EEHV Strategy Meeting. Wildlife Reserves Singapore Group

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes

Immunomodulatory and antimicrobial effects of vitamin C

Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management

Acyclovir-induced renal failure. Clinical course and histology

Use of famciclovir for the treatment of endotheliotrophic herpesvirus infections in Asian elephants (Elephas maximus)

Successful treatment of a clinical elephant endotheliotropic herpesvirus infection: The dynamics of viral load, genotype analysis, and treatment with acyclovir

First report of changes in leukocyte morphology in response to inflammatory conditions in Asian and African elephants (Elephas maximus and Loxodonta africana)

Development and validation of quantitative real-time polymerase chain reaction assays to detect elephant endotheliotropic herpesviruses-2, 3, 4, 5, and 6

Kinetics of viral loads and genotypic analysis of elephant endotheliotropic herpesvirus-1 infection in captive Asian elephants (Elephas maximus)

Detection of pathogenic elephant endotheliotropic herpesvirus in routine trunk washes from healthy adult Asian elephants (Elephas maximus) by use of a real-time quantitative polymerase chain reaction assay

Pharmacokinetics of acyclovir in adult horses

Using in-house hematology to direct decision-making in the successful treatment and monitoring of a clinical and subsequently subclinical case of elephant endotheliotropic herpesvirus 1B

Fatal herpesvirus hemorrhagic disease in wild and orphan asian elephants in southern India

CONFLICT OF INTEREST. We confirm there are no conflicts of interest.ACKNOWLEDGMENTS. The authors would like to thank the Assist International Service Co., Ltd. and Chiang Mai University for financial support. We also thank the owner of the calf who gave us permission to treat it and publish the results.